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Abciximab (ReoPro) removal during cardiopul-
monary bypass with a hemoconcentrator
To the Editor:
Poullis and colleagues1 recently presented their results of
an ex vivo study suggesting that a hemoconcentrator could be
used to remove the platelet glycoprotein IIb/IIIa (GPIIb/IIIa)
inhibitor abciximab (c7E Fab, ReoPro) during cardiopul-
monary bypass. On the basis of their findings, they state that
the use of a hemoconcentrator would reduce the need for
platelet transfusions and decrease the risk of bleeding in
patients recently treated with abciximab undergoing coronary
bypass. However, we believe their model incorporates severe
limitations that invalidate their findings.
The investigators state that the use of a hemoconcentrator
will remove “free ReoPro from the plasma.” They support
this conclusion through studies with a model that used either
saline solution or saline plus packed red blood cells to which
abciximab was added. However, because of the pharmacoki-
netics of abciximab, this model is not representative of a
patient treated with abciximab. In a patient, abciximab binds
with very high affinity (KD = 5 nmol/L) to the platelet
GPIIb/IIIa receptor, as well as to the α
v
β3 receptor found on
endothelial and smooth muscle cells2,3; any unbound mole-
cules of this monoclonal antibody fragment are cleared rapid-
ly from the plasma by the reticuloendothelial system.
Therefore free plasma concentrations of abciximab diminish
very rapidly after the termination of an infusion, with a half-
life of about 30 minutes.4,5 Thus, although in the model
described by Poullis’s group there was free abciximab avail-
able to be removed by the hemoconcentrator, this was
because they used solutions free of platelets or any other cells
to which the abciximab could bind. In a patient treated with
abciximab, there would be no unbound molecule available for
removal, and a hemoconcentrator would be of no benefit.
Aggressive platelet inhibition with GPIIb/IIIa inhibitors in
patients needing urgent cardiac surgery is certainly an appro-
priate concern. However, although anecdotal reports have
suggested a risk of excessive bleeding,6 results from recent
randomized trials have shown only a higher rate of platelet
transfusions in abciximab-treated patients, and, in fact, a
trend toward a decrease in death and perioperative myocar-
dial infarction compared with results in patients receiving
placebo.7
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Reply to the Editor:
We welcome the interest that our brief communication on
abciximab (ReoPro) removal1 has generated. Steinhubl,
Moore, and Lincoff raise a number of interesting issues:
First, we did not state that “a hemoconcentrator would
reduce the need for platelet transfusions and decrease the risk
of bleeding....” However, we did say that hemofiltration (1)
can remove free abciximab from a cardiopulmonary bypass
circuit, (2) can change the purpose of platelet replacement
from primarily absorbing free antibody to providing adequate
hemostasis, and (3) may result in a decreased risk of bleeding
during and after cardiac surgery. We make no claims to rever-
sal of the effect of abciximab on native platelets. However, by
implication from our results and the fact that abciximab bind-
ing is known to be a reversible process, hemofiltration may
result in at least a partial reversal of the effect of abciximab
on native platelets.2
Second, we agree that the pharmacokinetics of our study do
not match the in vivo situation. However, our aim was to
demonstrate that free abciximab could be removed with a
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hemofilter, thus reducing the inactivation of transfused
platelets. Abciximab does have a high affinity (KD) for gly-
coprotein IIb/IIIa; however, as this is a reversible binding,
removing the free abciximab will shift the equilibrium,
reducing the degree of platelet inhibition. Interpretation of
KD values can be misleading since the degree of binding is
not necessarily correlated with physiologic platelet inhibi-
tion that results, and the KD value can overestimate the bind-
ing activity caused by methodologic calcium ion artifacts.3
The binding of abciximab to the α
v
β3 receptor found on
endothelium and smooth muscle cells plays no role with
regard to hemostasis. However, the interaction may be very
beneficial from an anti-inflammatory, ischemia-reperfusion
perspective.
Third, with a half-life of about 30 minutes, free abciximab
will still be present at a sufficient concentration to inactivate
platelets 90 minutes after bolus administration. Obviously the
free concentration will be substantially higher if the abcix-
imab has been administered as a bolus followed by an infu-
sion (10 µg/min).
Fourth, the statement that no unbound molecules of abcix-
imab are available is untrue. This free pool is the source of
abciximab that inactivates transfused platelets,2 since
platelet-to-platelet transfer to abciximab is unlikely to occur
(this is microaggregation, which abciximab inhibits). In fact,
abciximab is administered as an infusion for the sole purpose
of maintaining a steady free plasma concentration of abcix-
imab to maintain platelet inhibition.2-4
Fifth, the series of Booth, Lincoff, and others5 provides
additional evidence that abciximab is associated with
increased bleeding, since a higher rate of blood transfusion
was required unless platelets were administered prophylacti-
cally. Only with some form of preoperative platelet function
testing is it valid to use anecdotal evidence of success or fail-
ure of operating on patients who have received abciximab
without any excessive bleeding. Unfortunately, because of
space limitations, the information in their abstract does not
specify the degree of platelet inhibition present in their
patients preoperatively, since it is well known that abciximab
has a variable clinical effect. Whole blood microaggregation
provides a quick, simple test of platelet inhibition caused by
abciximab, and it does not involve custom-made equipment
or conventional platelet function tests, which are impractical
in an emergency.6
A trial involving patients is the only answer to the possible
use of a hemoconcentrator after abciximab administration.
However, preoperative platelet function caused by abciximab
administration, time since administration, and patient
weight—all known risk factors—should be included, factors
not present in any publications so far.
A point of importance not raised by Steinhubl, Moore,
and Lincoff, however, is the concomitant administration of
other antiplatelet agents. Clopidogrel/ticlopidine and
aspirin are frequently combined in various regimens with
abciximab. Hemofiltration should have no effect on the out-
come of such complete and permanent blockage of platelet
function that is almost certainly present with such a combi-
nation.
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Transcutaneous extracorporeal cannulation for
bilateral lung transplantation without splitting the
sternum
To the Editor:
Bilateral sequential lung transplantation without sternal
division has recently been recommended as a less-invasive
approach than sternotomy.1,2 Two separate bilateral anterolat-
eral thoracotomies in selected patients eliminate post-trans-
plantation sternal complications and improve functional
recovery. Actually, this is our routine approach for bilateral
lung transplantation.
When cardiopulmonary bypass (CPB) is electively or
urgently required during the procedure, we use two differ-
ent approaches. Cannulation of the aorta and right atrium
can be done through a right thoracotomy or transcutaneous-
ly in the 3rd and 4th intercostal spaces. We report the case
of a patient requiring elective CPB in a bilateral lung trans-
plantation setting.
Clinical summary. A 49-year-old man with α1-antitrypsin
emphysema and secondary pulmonary hypertension (systolic
pulmonary artery pressure 80 mm Hg) was accepted for bilat-
eral lung transplantation. When a donor became available, we
